Cargando…

Derivation and Clinical Utility of Safety Targets for Linezolid-Related Adverse Events in Drug-Resistant Tuberculosis Treatment

Long-term usage of linezolid can result in adverse events such as peripheral neuropathy, anemia and thrombocytopenia. Therapeutic drug monitoring data from 75 drug-resistant tuberculosis patients treated with linezolid were analyzed using a time-to-event (TTE) approach for peripheral neuropathy and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Keutzer, Lina, Mockeliunas, Laurynas, Sturkenboom, Marieke G. G., Bolhuis, Mathieu S., Akkerman, Onno W., Simonsson, Ulrika S. H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10674798/ https://www.ncbi.nlm.nih.gov/pubmed/38004440 http://dx.doi.org/10.3390/ph16111575

Ejemplares similares

Model-Informed Precision Dosing of Linezolid in Patients with Drug-Resistant Tuberculosis
por: Mockeliunas, Laurynas, et al.
Publicado: (2022)

Mobile Health Apps for Improvement of Tuberculosis Treatment: Descriptive Review
por: Keutzer, Lina, et al.
Publicado: (2020)

Medical Device Apps: An Introduction to Regulatory Affairs for Developers
por: Keutzer, Lina, et al.
Publicado: (2020)

Individualized Dosing With High Inter-Occasion Variability Is Correctly Handled With Model-Informed Precision Dosing—Using Rifampicin as an Example
por: Keutzer, Lina, et al.
Publicado: (2020)

Standards for model-based early bactericidal activity analysis and sample size determination in tuberculosis drug development
por: Mockeliunas, Laurynas, et al.
Publicado: (2023)

A modeling‐based proposal for safe and efficacious reintroduction of bedaquiline after dose interruption: A population pharmacokinetics study
por: Keutzer, Lina, et al.
Publicado: (2022)

Linezolid-Associated Neurologic Adverse Events in Patients with Multidrug-Resistant Tuberculosis, France
por: Jaspard, Marie, et al.
Publicado: (2020)

Malnutrition assessment methods in adult patients with tuberculosis: a systematic review
por: ter Beek, Lies, et al.
Publicado: (2021)

Seasonal influence on respiratory tract infection severity including COVID‐19 quantified through Markov Chain modeling
por: van Wijk, Rob C., et al.
Publicado: (2023)

Reproducibility in pharmacometrics applied in a phase III trial of BCG-vaccination for COVID-19
por: van Wijk, Rob C., et al.
Publicado: (2023)

Proposed Linezolid Dosing Strategies to Minimize Adverse Events for Treatment of Extensively Drug-Resistant Tuberculosis
por: Imperial, Marjorie Z, et al.
Publicado: (2021)

Safety of Rifampicin at High Dose for Difficult-to-Treat Tuberculosis: Protocol for RIAlta Phase 2b/c Trial
por: Espinosa-Pereiro, Juan, et al.
Publicado: (2022)

Linezolid Trough Concentrations Correlate with Mitochondrial Toxicity-Related Adverse Events in the Treatment of Chronic Extensively Drug-Resistant Tuberculosis
por: Song, Taeksun, et al.
Publicado: (2015)

Use of Identical INN “Imiglucerase” for Different Drug Products: Impact Analysis of Adverse Events in a Proprietary Global Safety Database
por: Tsang, So-Fai, et al.
Publicado: (2022)

Linezolid for drug‐resistant pulmonary tuberculosis
por: Singh, Bhagteshwar, et al.
Publicado: (2019)

Clinical Utility of Contezolid-Containing Regimens in 25 Cases of Linezolid-Intolerable Tuberculosis Patients
por: Wang, Jun, et al.
Publicado: (2023)

Linezolid Pharmacokinetics and Its Association with Adverse Drug Reactions in Patients with Drug-Resistant Pulmonary Tuberculosis
por: Padmapriyadarsini, Chandrasekaran, et al.
Publicado: (2023)

Linezolid for Infants and Toddlers With Disseminated Tuberculosis: First Steps
por: Deshpande, Devyani, et al.
Publicado: (2016)

Low Rate of Acquired Linezolid Resistance in Multidrug-Resistant Tuberculosis Treated With Bedaquiline-Linezolid Combination
por: Du, Jian, et al.
Publicado: (2021)

Safety and Outcomes of Linezolid Use for Nocardiosis
por: Davidson, Natalie, et al.
Publicado: (2020)

Linezolid-resistant Mycobacterium tuberculosis: Will it impact the tuberculosis elimination programme?
por: Bharadwaj, Renu
Publicado: (2021)

Population pharmacokinetics and dose evaluations of linezolid in the treatment of multidrug-resistant tuberculosis
por: Zhang, Haoyue, et al.
Publicado: (2023)

Corrigendum to “Mass spectrometry for therapeutic drug monitoring of anti-tuberculosis drugs” [Clin. Mass Spectrom. 14(Part A) (2019) 34–45]
por: Kuhlin, Johanna, et al.
Publicado: (2022)

Fourteen-Day Bactericidal Activity, Safety, and Pharmacokinetics of Linezolid in Adults with Drug-Sensitive Pulmonary Tuberculosis
por: Diacon, Andreas H., et al.
Publicado: (2020)

Safety and efficacy of BCG re-vaccination in relation to COVID-19 morbidity in healthcare workers: A double-blind, randomised, controlled, phase 3 trial
por: Upton, Caryn M., et al.
Publicado: (2022)

Torsadogenic Risk of Antipsychotics: Combining Adverse Event Reports with Drug Utilization Data across Europe
por: Raschi, Emanuel, et al.
Publicado: (2013)

Linezolid for Treating Tuberculosis: A Delicate Balancing Act
por: Maartens, Gary, et al.
Publicado: (2015)

The critical role of background rates of possible adverse events in the assessment of COVID-19 vaccine safety
por: Black, Steven B., et al.
Publicado: (2021)

Machine Learning and Pharmacometrics for Prediction of Pharmacokinetic Data: Differences, Similarities and Challenges Illustrated with Rifampicin
por: Keutzer, Lina, et al.
Publicado: (2022)

Linezolid in the Starter Combination for Multidrug-Resistant Tuberculosis: Time to Move on to Group Four?
por: Grard, Soazic, et al.
Publicado: (2015)

Preclinical Evaluations To Identify Optimal Linezolid Regimens for Tuberculosis Therapy
por: Brown, Ashley N., et al.
Publicado: (2015)

Bedaquiline and Linezolid for Extensively Drug-Resistant Tuberculosis in Pregnant Woman
por: Jaspard, Marie, et al.
Publicado: (2017)

Pharmacodynamic Correlates of Linezolid Activity and Toxicity in Murine Models of Tuberculosis
por: Bigelow, Kristina M, et al.
Publicado: (2020)

Low-Dose Linezolid for Treatment of Patients With Multidrug-Resistant Tuberculosis
por: Mase, Anjeli, et al.
Publicado: (2022)

Linezolid pharmacokinetics in MDR-TB: a systematic review, meta-analysis and Monte Carlo simulation
por: Millard, James, et al.
Publicado: (2018)

Finding the right hazard function for time‐to‐event modeling: A tutorial and Shiny application
por: Van Wijk, Rob C., et al.
Publicado: (2022)

Evaluation of IL-1 Blockade as an Adjunct to Linezolid Therapy for Tuberculosis in Mice and Macaques
por: Winchell, Caylin G., et al.
Publicado: (2020)

Pro-Arrhythmic Potential of Oral Antihistamines (H1): Combining Adverse Event Reports with Drug Utilization Data across Europe
por: Poluzzi, Elisabetta, et al.
Publicado: (2015)

Concentration-Dependent Synergy and Antagonism of Linezolid and Moxifloxacin in the Treatment of Childhood Tuberculosis: The Dynamic Duo
por: Deshpande, Devyani, et al.
Publicado: (2016)

Adverse reaction report and retrospective analysis of black hairy tongue caused by linezolid
por: Luo, Shaohua, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_a5jeg6f35rfembk61tu8gktm41